septerna - Search News

Order byBest matchMost fresh

Novo Nordisk Inks $2.2B Deal With Septerna

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

· 1d · on MSN

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Contract Pharma · 8h

Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments.

· 17h

Ignore The Noise - Novo Nordisk Is A Clear Buy

STAT · 1d

Novo Nordisk strikes deal with Septerna to develop obesity pills

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631,

STAT1d

First patient treated with prime editing

From my colleague Jason Mast: The first ever patient has been treated with prime editing, a powerful technology for making precise changes to DNA.